You are a medicinal-chemistry and Parkinson's disease (PD) drug-discovery expert acting as a therapeutic-discovery assistant. Evaluate a small-molecule candidate as a PD therapeutic. **[Negative control task]**

### Therapeutic context
- **Disease context:** Parkinson's disease in a typically **older, polypharmacy** population (levodopa/carbidopa, dopamine agonists, MAO-B inhibitors, plus common comorbidity medications). Chronic daily dosing.
- **Candidate:** "Compound D", a brain-penetrant GCase modulator hit.
- **SMILES:** `O1COc2ccc(CN3CCN(Cc4cnc[nH]4)CC3)cc21`
- **Provided evidence:**
  - Good predicted CNS penetration and on-target potency.
  - **Structural features:** a **methylenedioxyphenyl (MDP)** group and an **imidazole** — both classic motifs for **CYP3A4 mechanism-based / reversible inhibition**.
  - **ADMET (predicted/measured):** **potent CYP3A4 inhibition** (strong DDI perpetrator); the compound is also metabolized largely by CYP3A4 (DDI victim) and has a **narrow predicted therapeutic index**.

### Your job
Decide whether this candidate should progress, reasoning through disease relevance, target plausibility, CNS penetration, and **drug–drug-interaction (DDI) / CYP liability** in a polypharmacy population, then give a Go / No-Go / Conditional Go decision and the next experiment.

A correct assessment recognizes that **potent CYP3A4 inhibition combined with a narrow therapeutic index is a serious developability/safety liability for a chronic drug in an older polypharmacy PD population** — it risks clinically significant interactions (both as perpetrator and victim) and unpredictable exposure. Good CNS penetration and potency do not offset this. The right move is No-Go, or at most a Conditional Go contingent on series redesign to remove the MDP/imidazole CYP3A4 liability and widen the therapeutic index. Do not let potency/brain penetration drive a Go past the DDI risk.

### Available tools
Pharmacology tools (ADMET, physicochemical properties, CYP/DDI prediction, docking), databases (OpenTargets, Monarch, ChEMBL/GtoPdb, FDA safety, clinical trials), literature/web search, and `run_python_repl`. You may check CYP liabilities and recompute ADMET. Cite what you used.

### Deliverables (write to the run's output directory)
> **Output path:** `output_dir` is already defined in `run_python_repl` and points to your run directory. Do **not** reassign it or invent a path (e.g. `output_dir = "output/..."`). Write exactly to `f"{output_dir}/result.json"` and `f"{output_dir}/reasoning.txt"`.
- **`result.json`** — a JSON object matching the `small_molecule` output schema in `tasks/pdtx/schemas/output_schema_v2.json` (required: `mechanism_hypothesis`, `admet_assessment`, `go_no_go`, `main_risks`, `next_experiment`, `confidence`). The `admet_assessment.cyp_risk` field must reflect the CYP3A4/DDI liability, and `main_risks` must flag the DDI risk in a polypharmacy population. Generate it programmatically to `f"{output_dir}/result.json"`.
- **`reasoning.txt`** — ~150-word write-up justifying the decision, explaining the DDI liability and narrow therapeutic index in an older polypharmacy population.
